.
BioEnterprise

BioMotiv to Receive $15 Million Investment from Biogen

Cleveland-based BioMotiv, the for-profit arm of The Harrington Project for Discovery & Development, raises $15 million from Biogen. The investment, to be made over five years, provides Biogen the exclusive rights to any neuroscience-related treatments that the company develops.

Read More  >